Changxin Li, MD
Internal Medicine · Gaylord, MINPI 1114958899
Payments from drug & device makers
Across 211 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$427
- Amgen$379
- AstraZeneca$320
- Boehringer Ingelheim$310
- Pfizer$294
- AbbVie$293
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,18598%
- Education$572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 32 | $427 |
| Amgen | 22 | $379 |
| AstraZeneca(2 entities) | 15 | $320 |
| Boehringer Ingelheim | 16 | $310 |
| Pfizer | 23 | $294 |
| AbbVie(2 entities) | 15 | $293 |
| GSK | 27 | $268 |
| Novartis | 10 | $160 |
| Johnson & Johnson | 8 | $113 |
| E.r. Squibb & Sons, L.L.C. | 6 | $83 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Astellas Pharma US Inc | 5 | $73 |
| Lilly USA, LLC | 5 | $65 |
| Sanofi-aventis U.S. LLC | 4 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Exact Sciences | 2 | $41 |
| Dexcom, Inc. | 2 | $41 |
| Bayer | 2 | $35 |
| Medtronic | 2 | $34 |
| Merck | 2 | $33 |
| Mylan Specialty L.p. | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Electromed, Inc. | 1 | $16 |
| Abbott | 1 | $14 |
| Strongbridge US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,242 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 148 | $244,544 |
| OzempicSemaglutide | 173 | $238,288 |
| JardianceEmpagliflozin | 153 | $210,521 |
| EliquisApixaban | 182 | $209,824 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 160 | $129,902 |
| TrulicityDulaglutide | 65 | $89,873 |
| FarxigaDapagliflozin Propanediol | 62 | $63,701 |
| XareltoRivaroxaban | 32 | $48,166 |
| JanuviaSitagliptin Phosphate | 22 | $34,010 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 141 | $33,807 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $29,100 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 39 | $25,698 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $18,494 |
| InvokanaCanagliflozin | 18 | $17,589 |
| LinzessLinaclotide | 18 | $16,935 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $65 | $338,765228 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta | $310 | $249,281208 claims |
| Novo NordiskOzempic | $427 | $238,288173 claims |
| PfizerEliquis | $294 | $209,824182 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $268 | $148,396193 claims |
| Johnson & JohnsonXarelto, Invokana | $113 | $65,75550 claims |
| AstraZenecaFarxiga | $320 | $63,70162 claims |
| MerckJanuvia | $33 | $34,01022 claims |
| AbbVieLinzess | $293 | $16,93518 claims |
| Astellas Pharma US IncMyrbetriq | $73 | $7,11813 claims |
| Sanofi-aventis U.S. LLCLantus | $63 | $4,40113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Gaylord
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.